The (B) case reveals that Sharer decided that Amgen should the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development

【書誌情報】

ページ数：4ページ

サイズ：A4

商品番号：HBSP-714426

発行日：2014/1/15

登録日：2015/7/15